Literature DB >> 32206301

Tin thiocarbonohydrazone complexes: synthesis, crystal structures and biological evaluation.

Jin Wang1, Yu-Ting Wang2, Yan Fang3, Yan-Li Lu3, Ming-Xue Li3.   

Abstract

In this article, three organotin complexes formulated as [(Me)2Sn(H2L1)] (1), [(Ph)2Sn(H2L1)]·MeOH (2) and [(Me)2Sn(HL2)(OAc)]4(Me)2O (3) (H4L1 = bis(2-hydroxybenzaldehyde) thiocarbohydrazone and H2L2 = bis(2-acetylpyrazine) thiocarbonohydrazone) have been synthesized and structurally characterized. Growth inhibition assays indicated that both the proligands and the three complexes are capable of showing anticancer activity against the human hepatocellular carcinoma HepG2 cells with H2L2 and complex 3 showing much higher cytotoxic potential. Subsequent toxicity studies on normal QSG7701cells showed that complex 3 has the highest tumor cell selectivity, and its IC50 value on QSG7701 cells is 8.48 fold higher than that in HepG2 cells. In acute toxicity experiments, complex 3 produces a dose-dependent effect in NIH mice with a LD50 value of 17.2 mg kg-1. This journal is © The Royal Society of Chemistry 2019.

Entities:  

Year:  2019        PMID: 32206301      PMCID: PMC7069364          DOI: 10.1039/c9tx00109c

Source DB:  PubMed          Journal:  Toxicol Res (Camb)        ISSN: 2045-452X            Impact factor:   3.524


  21 in total

1.  Observations on the antileukemic activity of pyridine-2-carboxaldehyde thiosemicarbazone and thiocarbohydrazone.

Authors:  R W BROCKMAN; J R THOMSON; M J BELL; H E SKIPPER
Journal:  Cancer Res       Date:  1956-02       Impact factor: 12.701

Review 2.  Chemistry and applications of organotin(IV) complexes of Schiff bases.

Authors:  Mala Nath; Pramendra K Saini
Journal:  Dalton Trans       Date:  2011-04-14       Impact factor: 4.390

3.  Azine-bridged octanuclear copper(II) complexes assembled with a one-stranded ditopic thiocarbohydrazone ligand.

Authors:  Diana Dragancea; Vladimir B Arion; Sergiu Shova; Eva Rentschler; Nicolae V Gerbeleu
Journal:  Angew Chem Int Ed Engl       Date:  2005-12-09       Impact factor: 15.336

4.  Synthesis, structures and anti-malaria activity of some gold(I) phosphine complexes containing seleno- and thiosemicarbazonato ligands.

Authors:  Anja Molter; Jörg Rust; Christian W Lehmann; Ganesh Deepa; Peter Chiba; Fabian Mohr
Journal:  Dalton Trans       Date:  2011-08-30       Impact factor: 4.390

Review 5.  Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity.

Authors:  R A Finch; M C Liu; A H Cory; J G Cory; A C Sartorelli
Journal:  Adv Enzyme Regul       Date:  1999

6.  Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.

Authors:  Scott Wadler; Della Makower; Caroline Clairmont; Paula Lambert; Karen Fehn; Mario Sznol
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  L- and D-proline thiosemicarbazone conjugates: coordination behavior in solution and the effect of copper(II) coordination on their antiproliferative activity.

Authors:  Miljan N M Milunovic; Éva A Enyedy; Nóra V Nagy; Tamás Kiss; Robert Trondl; Michael A Jakupec; Bernhard K Keppler; Regina Krachler; Ghenadie Novitchi; Vladimir B Arion
Journal:  Inorg Chem       Date:  2012-08-13       Impact factor: 5.165

8.  A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.

Authors:  Joshua F Zeidner; Judith E Karp; Amanda L Blackford; B Douglas Smith; Ivana Gojo; Steven D Gore; Mark J Levis; Hetty E Carraway; Jacqueline M Greer; S Percy Ivy; Keith W Pratz; Michael A McDevitt
Journal:  Haematologica       Date:  2013-12-20       Impact factor: 9.941

9.  A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.

Authors:  M J Mackenzie; D Saltman; H Hirte; J Low; C Johnson; G Pond; M J Moore
Journal:  Invest New Drugs       Date:  2007-06-22       Impact factor: 3.850

10.  COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.

Authors:  Kowthar Y Salim; Saman Maleki Vareki; Wayne R Danter; James Koropatnick
Journal:  Oncotarget       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.